BEIJING, Dec. 18, 2014
/PRNewswire/ -- Elekta (EKTA-B.ST) announces that the China
Food and Drug Administration (CFDA) has approved Elekta's
Flexitron® brachytherapy afterloading platform for sale
and marketing in China.
In China there is a high
prevalence of gynecologic cancers, as well lung, breast, colorectum
and esophagus cancers. Many patients with such cancers can be
effectively treated with brachytherapy. With the introduction of
Flexitron®, hundreds of thousands of cancer patients can
benefit from being treated with this new, advanced afterloading
platform.
For hospitals offering brachytherapy, Flexitron® can
reduce workflow complexity and improve efficiency. It is
revolutionizing safety and workflow in the modern brachytherapy
practice. By being designed around an upgradable architecture,
Flexitron represents a truly safe investment for the future.
Anming Gong, Elekta's Managing
Director for China, says: "Elekta
is happy to introduce to China an effective brachytherapy
solution – especially for gynecologic cancers. The timing is
perfect as recently published guidelines from the 2014 CSTRO/SANTRO
Symposium in October state that brachytherapy is a key technique
for cervical cancer treatment and is instrumental in improving the
control and survival rates of women with these cancers."
There are about 130,000 new cervical cancer patients per year in
China and about 40,000 Chinese
patients are treated with brachytherapy annually.
Elekta offers complete brachytherapy solutions, including
afterloading platforms, applicators and treatment planning. For
Asian patients in particular, Elekta has developed dedicated small
applicators designed to fit their anatomy.
For further information, please contact:
Gert van Santen, Group Vice President Corporate
Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Kris Walmsley, Corporate
Communications Manager, Elekta
AB
Tel: +46 70 537 9545, e-mail: kris.walmsley@elekta.com
Time zone: CET: Central European Time
About Elekta
Elekta is a human care company pioneering
significant innovations and clinical solutions for treating cancer
and brain disorders. The company develops sophisticated,
state-of-the-art tools and treatment planning systems for radiation
therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence
to both health care providers and patients, Elekta aims to improve,
prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in
over 6,000 hospitals worldwide. Elekta employs around 3,800
employees globally. The corporate headquarters is located in
Stockholm, Sweden, and the company
is listed on NASDAQ Stockholm. Website: www.elekta.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/elekta-flexitron-brachytherapy-treatment-delivery-available-in-china-300011764.html
SOURCE Elekta